Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Classification01:23

Modified-Release Drug Delivery Systems: Classification

306
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
306
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

228
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
228
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

288
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
288
Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

128
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
128
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

594
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
594
Modified-Release Drug Delivery Systems: Stimuli-Activated01:30

Modified-Release Drug Delivery Systems: Stimuli-Activated

168
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
168

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

New Treatments for Migraine-Therapeutic Ratings and Comparative Coverage in the US, Canada, and Europe.

JAMA internal medicine·2021
Same author

Raising Medicaid Rebates For Drugs With Accelerated Approval.

Health affairs (Project Hope)·2021
Same author

Payer-Specific Negotiated Prices for Prescription Drugs at Top-Performing US Hospitals.

JAMA internal medicine·2021
Same author

How Should Clinicians and Organizations Assess Risks and Benefits of First-in-Human Implantation of Investigational Devices?

AMA journal of ethics·2021
Same author

Characteristics of US Patients and Prescribers Using Hydroxychloroquine During the COVID-19 Pandemic.

Journal of general internal medicine·2021
Same author

Value-based pricing of drugs with multiple indications or in combinations - lessons from Europe.

Nature reviews. Clinical oncology·2021

Related Experiment Video

Updated: Apr 23, 2026

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

4.4K

Electronic medication packaging devices and medication adherence: a systematic review.

Kyle D Checchi1, Krista F Huybrechts1, Jerry Avorn1

  • 1Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

JAMA
|September 24, 2014
PubMed
Summary

Electronic medication packaging (EMP) devices may improve medication adherence for chronic conditions. Systems integrated into healthcare, recording dosing events, showed the most promise, though more high-quality research is needed.

More Related Videos

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
04:34

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia

Published on: February 17, 2023

1.9K
Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

1.5K

Related Experiment Videos

Last Updated: Apr 23, 2026

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

4.4K
Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
04:34

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia

Published on: February 17, 2023

1.9K
Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

1.5K

Area of Science:

  • Health Informatics
  • Medication Adherence Research
  • Digital Health Interventions

Background:

  • Medication nonadherence affects a significant portion of patients with chronic conditions like hypertension, hyperlipidemia, and diabetes.
  • Electronic medication packaging (EMP) devices, designed to monitor adherence, offer a potential solution to improve patient compliance.

Purpose of the Study:

  • To evaluate the effectiveness of EMP devices in improving medication adherence.
  • To identify and characterize common features of existing EMP devices.

Main Methods:

  • A systematic review of 37 peer-reviewed studies (32 randomized, 5 non-randomized) involving 4326 patients was conducted.
  • Studies were sourced from multiple databases (MEDLINE, EMBASE, PsycINFO, CINAHL, etc.) up to June 2014.
  • Bias assessment used the Cochrane Handbook; EMP device features were qualitatively analyzed.

Main Results:

  • Intervention effects on adherence varied, with mean adherence differences ranging from -2.9% to +34.0% and adherent proportion differences from -8.0% to +49.5%.
  • Common EMP features include recorded dosing events, audiovisual reminders, digital displays, real-time monitoring, and adherence feedback.
  • Complex interventions integrated into healthcare systems and recording dosing events were most associated with adherence improvement.

Conclusions:

  • Diverse EMP devices are available, but supporting evidence is limited and study quality varies.
  • Devices that integrate into care delivery and record dosing events show the most consistent association with improved adherence.
  • Further high-quality research is necessary to confirm the efficacy of EMP devices and optimize their components for medication nonadherence.